Appointments
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: Global Aesthetics Head Exits Allergan for Merz, C-Level Commercial Changes at Flexion And Karyopharm
Merz Pharma Group’s Merz Aesthetics welcomes former Allergan exec as new chief scientific officer. Meanwhile, a chief commercial officer is appointed at Flexion Therapeutics, developer of treatments for musculoskeletal conditions, and at Karyopharm Therapeutics, an oncology-focused pharma.
Executives On The Move: UCB Announces Future Financial Leadership Change And Analytics Experience for Corbus Pharma
Corbus Pharmaceuticals, developer of therapeutics for inflammatory and fibrotic diseases, hires EMD Serono exec as head of commercial ops and analytics. Also, multinational biopharma UCB to have a new CFO in July.
Executives On The Move: Bayer Elects New Chairman, J&J Vision Exec Makes A Change for Eyevance And CureVac Decides On Candidate For Rare Diseases Post
Bayer AG elects a new chairman, to begin serving at the end of April. US ophthalmic products firm Eyevance Pharma brings on board a former J&J Vision exec as chief commercial officer, and German mRNA company CureVac AG appoints a new head of rare diseases.
Executives On The Move: Change At The Top For Endo And Santen, And Corporate Restructuring At Sanofi
Generics and specialty pharma Endo International and Japanese ophthalmic product company Santen Pharmaceutical each announce a new CEO. Meanwhile, restructuring at Sanofi results in departures of Chief Digital and Medical Officer, and EVPs of Primary Care, Business Transformation and External Affairs.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.
More Top-Level Pharma Changes In India, Cipla Gets CSO
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
Executives On The Move: Eisai Taps Celgene And Sanofi VPs For Its Team, And Freeline Selects A CEO
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.
Ex-Janssen India Chief To Lead PE-Controlled Bharat Serums
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co.
Takeda Vaccines VP switches to cancer immunotherapy and vaccine company Bavarian Nordic and Novartis Institutes exec moves to molecular medicines firm Boston Pharmaceuticals, each in the CMO position. Meanwhile, Merck & Co will add a scientific and a strategic expert to its board.
Executives On The Move: Bayer Names Upcoming Information Chief And Legal Hires At Eli Lilly And CytoDyn
Stryker tech officer will become Bayer AG’s chief information technology and digital transformation Officer in June. In addition, monoclonal antibody therapy firm CytoDyn and global pharma Eli Lilly each hire a general counsel.
Freeline Bags Alnylam's Heggie As CEO
Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.
Cipla Rejigs Executives, New Chief For North America Business
Ex-Torrent COO Arunesh Verma to lead Cipla’s North America generics business, while the head of Cipla USA has been repositioned to lead the India prescription business, among other personnel changes.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.